Literature DB >> 30593878

Regulation of P2X7 receptor expression and function in the brain.

Eva M Jimenez-Mateos1, Jonathon Smith2, Annette Nicke3, Tobias Engel2.   

Abstract

Because of its prominent role in driving inflammatory processes, the ATP-gated purinergic P2X7 receptor has attracted much attention over the past decade as a potential therapeutic target for numerous human conditions, particularly diseases of the central nervous system, including neurodegenerative diseases (e.g. Alzheimer's and Huntington's disease), psychiatric disorders (e.g. schizophrenia and depression) and the neurological disease, epilepsy. Evidence stems from studies using experimental models and patient tissue showing changes in P2X7 expression and function under pathological conditions and beneficial effects provided by P2X7 antagonism. Apart from promoting neuroinflammation, P2X7, however, also impacts on other pathological processes in the brain, including cell death, hyperexcitability, changes in neurotransmitter release and neurogenesis. Reports also suggest a role for P2X7 in the maintenance of blood-brain-barrier integrity. It therefore comes as no surprise that the regulation of P2X7 expression and function is complex, providing tight control on P2X7 activation. Much progress has been made in understanding how P2X7 is regulated during physiological and pathological conditions and what the consequences are of pathological P2X7 expression and function. Regulatory mechanisms altering P2X7 expression include transcriptional and post-translational regulation including nucleotide polymorphisms, promoter regulation via DNA methylation, transcription factors (e.g. Sp1 and HIF-1α), the generation of different splice variants and receptor phosphorylation, glycosylation and palmitoylation. Finally, more recently, reports have also shown P2X7-targeting by microRNAs, blocking P2X7 translation into functional proteins. The present review provides a broad overview of what is known to-date about the complex regulation of P2X7 expression with a particular emphasis on the brain and how each of these regulatory mechanisms impacts on receptor function and pathology.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ATP; Brain; Expression; Purinergic P2X7 receptor

Year:  2018        PMID: 30593878     DOI: 10.1016/j.brainresbull.2018.12.008

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  24 in total

1.  Functional P2X7 Receptors in the Auditory Nerve of Hearing Rodents Localize Exclusively to Peripheral Glia.

Authors:  Silvia Prades; Gregory Heard; Jonathan E Gale; Tobias Engel; Robin Kopp; Annette Nicke; Katie E Smith; Daniel J Jagger
Journal:  J Neurosci       Date:  2021-02-09       Impact factor: 6.167

2.  Ca2+ flux through splice variants of the ATP-gated ionotropic receptor P2X7 is regulated by its cytoplasmic N terminus.

Authors:  Xin Liang; Damien S K Samways; Jane Cox; Terrance M Egan
Journal:  J Biol Chem       Date:  2019-06-27       Impact factor: 5.157

3.  P2Y12 receptor gene polymorphisms are associated with epilepsy.

Authors:  Qi Wang; Nan-Rui Shi; Peng Lv; Juan Liu; Ji-Zhou Zhang; Bin-Lu Deng; Yan-Qin Zuo; Jie Yang; Xin Wang; Xiang Chen; Xiu-Min Hu; Ting-Ting Liu; Jie Liu
Journal:  Purinergic Signal       Date:  2022-02-17       Impact factor: 3.765

4.  The P2X7 receptor antagonist JNJ-47965567 administered thrice weekly from disease onset does not alter progression of amyotrophic lateral sclerosis in SOD1G93A mice.

Authors:  Diane Ly; Anjila Dongol; Peter Cuthbertson; Thomas V Guy; Nicholas J Geraghty; Reece A Sophocleous; Lucia Sin; Bradley J Turner; Debbie Watson; Justin J Yerbury; Ronald Sluyter
Journal:  Purinergic Signal       Date:  2020-03-13       Impact factor: 3.765

Review 5.  Purinergic Receptors in Basal Ganglia Diseases: Shared Molecular Mechanisms between Huntington's and Parkinson's Disease.

Authors:  Talita Glaser; Roberta Andrejew; Ágatha Oliveira-Giacomelli; Deidiane Elisa Ribeiro; Lucas Bonfim Marques; Qing Ye; Wen-Jing Ren; Alexey Semyanov; Peter Illes; Yong Tang; Henning Ulrich
Journal:  Neurosci Bull       Date:  2020-10-07       Impact factor: 5.203

Review 6.  Role of purines in regulation of metabolic reprogramming.

Authors:  Zhenwei Tang; Wenrui Ye; Haotian Chen; Xinwei Kuang; Jia Guo; Minmin Xiang; Cong Peng; Xiang Chen; Hong Liu
Journal:  Purinergic Signal       Date:  2019-09-06       Impact factor: 3.765

7.  Characterization of the Expression of the ATP-Gated P2X7 Receptor Following Status Epilepticus and during Epilepsy Using a P2X7-EGFP Reporter Mouse.

Authors:  James Morgan; Mariana Alves; Giorgia Conte; Aida Menéndez-Méndez; Laura de Diego-Garcia; Gioacchino de Leo; Edward Beamer; Jonathon Smith; Annette Nicke; Tobias Engel
Journal:  Neurosci Bull       Date:  2020-09-07       Impact factor: 5.203

8.  Editorial: P2X7 as Common Therapeutic Target in Brain Diseases.

Authors:  Tobias Engel; Annette Nicke; Jan M Deussing; Beata Sperlagh; Miguel Diaz-Hernandez
Journal:  Front Mol Neurosci       Date:  2021-04-27       Impact factor: 5.639

9.  Mapping the Site of Action of Human P2X7 Receptor Antagonists AZ11645373, Brilliant Blue G, KN-62, Calmidazolium, and ZINC58368839 to the Intersubunit Allosteric Pocket.

Authors:  Anfal Bin Dayel; Richard J Evans; Ralf Schmid
Journal:  Mol Pharmacol       Date:  2019-07-01       Impact factor: 4.436

Review 10.  Update of P2X receptor properties and their pharmacology: IUPHAR Review 30.

Authors:  Peter Illes; Christa E Müller; Kenneth A Jacobson; Thomas Grutter; Annette Nicke; Samuel J Fountain; Charles Kennedy; Günther Schmalzing; Michael F Jarvis; Stanko S Stojilkovic; Brian F King; Francesco Di Virgilio
Journal:  Br J Pharmacol       Date:  2020-12-21       Impact factor: 9.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.